Fredun Pharmaceuticals Reports Strong Sales Growth Amid Rising Interest Expenses in March 2025

Fredun Pharmaceuticals has recently reported its financial results for the quarter ending March 2025, showcasing notable developments in its performance metrics. The company has experienced a positive shift in its evaluation, with its score reflecting an adjustment from the previous quarter.
In terms of net sales, Fredun Pharmaceuticals achieved Rs 167.41 crore, marking a significant year-on-year growth of 41.84%. This figure represents the highest sales recorded in the last five quarters, indicating a robust near-term sales trend. The operating profit also reached a peak of Rs 17.44 crore, further underscoring the company's strong performance in this period.

Profit before tax (PBT) and profit after tax (PAT) both reached their highest levels in five quarters, with PBT at Rs 8.04 crore and PAT at Rs 7.07 crore, reflecting year-on-year growth rates of 37.67% and 39.7%, respectively. Additionally, earnings per share (EPS) climbed to Rs 14.98, highlighting increased profitability for shareholders.

However, the company faces challenges as interest expenses rose to Rs 8.15 crore, the highest in five quarters, indicating a potential strain on financial management. The operating profit to interest ratio has also reached its lowest point in the same timeframe, suggesting difficulties in managing interest payments.

For further insights into Fredun Pharmaceuticals' financial trends and evaluations, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.